# SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome

> **NCT00495547** · PHASE2 · TERMINATED · sponsor: **PETHEMA Foundation** · enrollment: 16 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Beta Erythropoietin

## Key facts

- **NCT ID:** NCT00495547
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-04-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00495547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00495547, "SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00495547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*